News

Under the terms of the collaboration, Lonza will provide DiNAQOR preclinical, clinical and commercial production support for the company’s lead preclinical program DiNA-001, an adeno-associated virus (AAV) gene therapy program

Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.2,3 The medicine is expected to

The Japanese conglomerate plans to acquire Veloxis Pharmaceuticals through its Danish subsidiary Asahi Kasei Pharma Denmark in a move to accelerate its transformation into a global healthcare company.

In this connection, Ferring Pharmaceuticals has launched a new company FerGene, which will focus on the global development and US commercialisation of nadofaragene firadenovec. The gene therapy is

Health officials have identified MDR gonorrhea, a sexually transmitted bacteria, as an urgent global public health threat, exacerbated by limited diagnostics and treatment options. Each year, according to

The late-breaking data were presented by Nicholas Butowski, M.D., a principal investigator on the trial and Professor of Neurological Surgery at the University of California San Francisco Weill

Remsima SC is claimed to be the world’s first subcutaneous formulation of infliximab. The EC approval was based on clinical evidence, including results from a study that demonstrated

The late-stage trial called IMbrave150 evaluated the Tecentriq, Avastin combination in comparison with sorafenib in 501 patients with unresectable HCC, who did not receive prior systemic therapy. Data

Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD. The designation of psilocybin as a Breakthrough Therapy for MDD acknowledges